Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Comparative Hepatology|February 26, 2010
Chlamydia trachomatis growth inhibition and restoration of LDL-receptor level in HepG2 cells treated with mevastatinYuriy K Bashmakov, Nailya A Zigangirova, Yulia P Pashko, et al.
Advances in Clinical and Experimental Medicine : Official Organ Wroclaw Medical University|August 29, 2014
Chlamydia trachomatis promotes 3T3 cell differentiation into adipocytesIvan M Petyaev, Nailya A Zigangirova, Lydia N Kapotina, et al.
The Journal of Antibiotics|January 22, 2021
Fluorothiazinon, a small-molecular inhibitor of T3SS, suppresses salmonella oral infection in miceNailya A Zigangirova, Ludmila N Nesterenko, Anna B Sheremet, et al.
The Journal of Antibiotics|January 22, 2022
Preventative treatment with Fluorothiazinon suppressed Acinetobacter baumannii-associated septicemia in miceNataliya E Bondareva, Anna V Soloveva, Anna B Sheremet, et al.
The Journal of Antibiotics|April 1, 2026
Long-term lung infection suppression in a mouse model caused via the clinical isolate of Burkholderia cenocepacia using the non-traditional antibacterial agent FluorothiazinoneAnna V Soloveva, Stanislava A Nelyubina, Elena Yu Morgunova, et al.
The Journal of Antibiotics|January 7, 2016
A small-molecule compound belonging to a class of 2,4-disubstituted 1,3,4-thiadiazine-5-ones suppresses Salmonella infection in vivoLudmila N Nesterenko, Nailya A Zigangirova, Egor S Zayakin, et al.
International Journal of Molecular Sciences|September 13, 2025
Chronic Escherichia coli ST648 Infections in Patients with Cystic Fibrosis: The In Vitro Effects of an Antivirulence AgentOlga L Voronina, Marina S Kunda, Natalia N Ryzhova, et al.
Journal of Pharmaceutical and Biomedical Analysis|October 1, 2023
Pharmacokinetics, quorum-sensing signal molecules and tryptophan-related metabolomics of the novel anti-virulence drug Fluorothiazinon in a Pseudomonas aeruginosa-induced pneumonia murine modelMark V Savitskii, Natalia E Moskaleva, Alex Brito, et al.
Pharmaceutical Research|October 1, 2025
Single- and Multiple-dose Pharmacokinetics, Excretion, Metabolism, and Safety of the Antivirulence Agent Fluorothiazinone in Healthy AdultsMark V Savitskii, Natalia E Moskaleva, Svetlana A Appolonova, et al.
The Journal of Antibiotics|March 16, 2024
Pharmacokinetics, tissue distribution, bioavailability and excretion of the anti-virulence drug Fluorothiazinon in rats and rabbitsMark V Savitskii, Natalia E Moskaleva, Alex Brito, et al.
Pageof 2